Nine therapies have outgrown the IPM growth
The Indian Pharmaceutical Market (IPM) clocked Rs 8281 crores in August 2015. It grew at 13 per cent in the same month. Amongst the top 10, Lupin grew by 21.2 per cent followed by Pfizer at 19.5 per cent and Abbott at 13.7 per cent. 22 corporates have crossed the growth of IPM for the month of August 2015 amongst top 50.
Amongst the top 50 corporates, AstraZeneca had the highest growth of 55.7 per cent followed by Bharat Serums at 38.9 per cent and MSD at 34.2 per cent. 32 corporates have shown growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Intas had the highest growth of 31 per cent followed by Glenmark at 28 per cent and Torrent at 21.7 per cent.
Amongst the 21-30 ranked corporates, MSD had the highest growth at 34.2 per cent followed by Wockhardt 24.6 per cent and Novartis at 16 per cent. Amongst the 31-40 ranked corporates, AstraZeneca had the highest growth at 55.7 per cent followed by Bharat Serums at 38.9 per cent and JBCPL at 19.3 per cent.
Amongst the 41-50 ranked corporates, Allergan had the highest growth at 21.8 per cent followed by Fourrts at 15.4 per cent and Walace at 15 per cent. Amongst the 51-60 ranked corporates, Boehringer grew at 98 per cent followed by Eli Lilly at 41.7 per cent and Troikaa at 39.2 per cent.
Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 39.6 per cent followed by TTK by 19.2 per cent followed by RPG at 14.8 per cent. Centaur has entered the Rs 300-crore club on MAT basis.
For the month of August 2015, amongst the top 10, Lupin grew by 21.2 per cent followed by Pfizer at 19.5 per cent and Sun Pharma at 15 per cent. 24 companies have crossed the growth of IPM amongst top 50. Amongst the 21-30 ranked companies, Wockhardt had the highest growth at 24.6 per cent followed by Novo Nordisk at 22.5 per cent and Zuventus at 16.9 per cent.
Indian companies have grown at 12.4 per cent versus 15.1 per cent for MNCs in August 2015. Amongst the top 50 in MNCs, AstraZeneca grew at 55.7 per cent, MSD grew by 34.2 per cent followed by Allergan at 21.8 per cent. Under the Non-NLEM category, Indian companies grew at 13.8 per cent whereas MNCs grew at 16.9 per cent.
The DPCO containing molecules market grew at 3.3 per cent whereas the non-DPCO market grew by 14.5 per cent and Non-Sch Para 19 Market at 15.2 per cent resulting in an overall growth of 13 per cent for August 2015. NLEM and Non – NLEM category showed unit growth at -2.7 per cent and 2.4 per cent respectively. The Non-Sch Para 19 Market grew at 13.7 per cent from units perspective.
From therapy perspective, nine therapies have outgrown the IPM growth. The respiratory market grew at 2.7 per cent, gastrointestinal market grew at 15.3 per cent, pain and analgesics market grew at 10.8 per cent whereas anti-infectives grew at 2.2 per cent. The anti-diabetic market grew at 25.6 per cent and cardiac at 18.7 per cent in chronic business. The derma market grew by 19 per cent and urology market at 18.5 per cent.
From regional perspective, 13 regions have outgrown the IPM growth. The Tamil Nadu market grew the highest at 26.2 per cent followed by Mumbai city market at 23.4 per cent and Odisha market at 22.7 per cent.
Two regions had negative growth in August 2015. Amoxycillin + Clavulanic Acid Market grew at minus one per cent whereas Glimepiride + Metformin grew at 15.8 per cent at number two.
The markets of paracetamol grew at 8.4 per cent, Atorvastatin 10.3 per cent, probiotic microbes at 32.4 per cent, Cefixime -7.2 per cent, pantoprazole 15.1 per cent, montelukast + levocetrizine at 9.5 per cent, glimepiride + metformin + pioglitazone at 21.1 per cent, Vitamin-D at 36.8 per cent, hydroquinone + mometasone + tretinoin at 12.3 per cent, voglibose + metformin + glimepiride at 51.9 per cent, rosuvastatin at 27.7 per cent, protein supplements at 10.5 per cent, azithromycin at -9.8 per cent, calcium carbonate + Vit D3 market at 27.6 per cent.
Mixtard leads the pack with Rs 39 crores followed by Corex, Monocef and Augmentin at Rs 27 crores for August 2015. Corex grew at 46.1 per cent followed by Mixtard at 21 per cent amongst top five brands.
Few brands who have gained ranks include Chymoral Forte (+148), Trajenta (+65), Vertin (+58), Magnex (+48), Omez (+43), Huminsulin (+41), Betnovate C (+39), Janumet (+37), Betnesol (+29), Panderm Plus, Rosuvas (+28), Jalra (+24), Ultracet (+23), Jalra M (+20), Januvia, Istamet (+19), Betnovate N, Rantac (+17), Pantop, Tonact (+16), Shelcal, Telma (+15), Zoryl M (+14), Galvus Met, Pan, Levipil, Aztor, Galvus (+12), Pan D, Telma H, Dolo (+11), Corex, Pantocid D SR (+10) amongst top 100 Brands over August -14
Few brands that have moved up ranks fastest into Top 300 Brands for the month of August 2015 are Biovac V, Brilinta, Oframax, Vaxigrip, Omnacortil, Bevon amongst others. 300th biggest brand is Nexpro from Torrent.
A total of 229 brands and 368 SKUs were launched in August 2015. Top new brands for August 2015 are Aztolet, Qilib, New Asthalin. Biggest new launch by an MNC are Qilib, Metosan, Pentashield in August 2015.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
